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Background: Cardiac sarcoidosis (CS) is a rare but potentially fatal condition that may present with advanced heart failure. However, effectiveness 
of cardiac resynchronization therapy (CRT) on patients with CS remains unclear.
methods: We evaluated echocardiographic reverse remodeling at 6-month follow-up in patients with CS and other non-ischemic cardiomyopathy, 
who enrolled in the CUBIC study which is a Japanese multi-center CRT registry.
results: Among consecutive 995 patients from CUBIC study, we picked up and investigated 553 patients who were diagnosed as non-ischemic 
cardiomyopathy and were available with appropriate echocardiographic data at pre and 6-month after CRT implantation (age: 67.6±11.8 years, 
female gender: 37%, NYHA: 2.8±0.5, QRS width: 156.6±32.7ms,left ventricular ejection fraction: 27.9±10.1% and CRT-D: 64%). Among the patients 
of non-ischemic cardiomyopathy, comparisons were performed between patients with CS (CS group, n=25 (4.5%)) and without CS (non-CS group, 
n=528 (95.5%)). Responder for CRT was defined as LVESV reduction ≥15%. CRT responder rate was significantly lower in CS group compared 
with non-CS group (36% vs. 61%, p=0.012). LVESV reduction volume and rate were significantly smaller in CS group compared with non-CS group 
(30.1±29.8 ml vs. 32.5±49.1 ml, p=0.031, and 12.4% vs. 20.2%, p=0.027, respectively).
conclusion: Among the CRT patients with non-ischemic cardiomyopathy, CS accounted for 4.5%. Their response to CRT was poor compared with 
non-CS patients. Further analyzed data to predict responders in CS patients will be presented at the meeting.
